Abstract:Background: Copy-number alterations (CNAs) are a key hallmark of cancer and play a major role in chemotherapy resistance. Earlier studies aiming to identify genes with CNA-associated expression levels do not explicitly quantify the degree of CNA regulation on expression levels, leading to an overabundance of false positive discoveries. To overcome this, we propose a robust statistical method to quantify the impact of CNAs on gene expression levels, thereby addressing a longstanding unresolved issue of the relevance of CNA exerted regulation to expression levels at gene and pathway levels. Materials and methods: We used whole-genome sequencing (WGS) and RNA-seq data from 263 matched samples of 93 HGSC patients in the prospective, longitudinal and observational DECIDER clinical trial (ClinicalTrials.gov identifier: NCT04846933). To discover genes and pathways whose activity is regulated by CNAs, we developed copy-number regulation (CNR) analysis that is based on nonlinear monotonic Poisson regression model. The KRAS down-regulation and up-regulation experiments were done in KURAMOCHI and CAOV3 cell lines, respectively, using CRISPR technology. Results: The CNR analysis identified several pathways that are driven by genes whose expression levels are regulated by CNAs. These pathways were further divided into four classes based on the number of CNAs and the degree of regulation due to CNAs. Six pathways characterized by high CNAs and high CNA regulation were associated to survival. Interestingly, in three of them the pathway activity was driven by wild-type KRAS amplification (wtKRASamp). KRAS expression was significantly associated with poor overall survival in the DECIDER and TCGA cohorts, whereas KRAS amplification alone was not. To functionally test the effect of KRAS amplification on platinum response, we mimicked the modulation of KRAS CNAs by CRISPR perturbation in cell lines. Our findings demonstrate that KRAS plays a functional role in platinum resistance and suggest wtKRASamp induced chemoresistance as a putative cause for treatment resistance in patients with high KRAS expression. KRAS mutations were not detected in any patient in the DECIDER cohort. Conclusions: We have developed an approach that enables quantifying gene copy-number regulation, i.e., revealing CNAs that have a strong impact on gene expression values. This allows pinpointing the genes and pathways that are likely to be play crucial roles in cancer progression and therapy resistance, as abundant CNAs alone can lead to high levels of noise and manifests in passenger findings. Our approach also provides a means to identify the most important copy-number alterations contributing to pathway dysregulation. This enables elucidating the context for genes whose activity is highly influenced by CNAs. Importantly, our results underscore the role of wtKRASamp, which is amplified with high expression in 13% of the patients in the DECIDER cohort, in driving chemotherapy resistance in HGSC. Citation Format: Sampsa Hautaniemi, Sanaz Jamalzadeh, Jun Dai, Kari Lavikka, Yilin Li, Kaisa Huhtinen, Anni Virtanen, Jaana Oikkonen, Sakari Hietanen, Johanna Hynninen, Anna Vähärautio, Antti Häkkinen. Genome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma [abstract]. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_2) nr A027.

High-resolution Analysis of Copy Number Alterations and Associated Expression Changes in Ovarian Tumors.

Genome-wide Analysis of Common Copy Number Variation and Epithelial Ovarian Cancer Risk.

Genome-Wide Association Study Of Copy Number Variations In Serous Epithelial Ovarian Cancer Susceptibility

Identification of Recurrent Focal Copy Number Variations and Their Putative Targeted Driver Genes in Ovarian Cancer

Abstract 6065: Patterns of Dysregulated Coding and Noncoding Gene Expression in High-Grade Serous Ovarian Carcinomas

Prognostic Relevance of Copy Number Losses in Ovarian Cancer

High-Resolution Genomic And Expression Analyses Of Copy Number Alterations In Breast Tumors

Exome Genotyping Arrays to Identify Rare and Low Frequency Variants Associated with Epithelial Ovarian Cancer Risk.

Abstract 4343: Revealing ovarian cancer copy number variation in single cells

Data from Analysis of DNA Copy Number Alterations in Ovarian Serous Tumors Identifies New Molecular Genetic Changes in Low-Grade and High-Grade Carcinomas

Integrated genomic analyses of ovarian carcinoma

Genome-wide Somatic Copy Number Alteration Analysis and Database Construction for Cervical Cancer.

Copy Number Aberrations from Affymetrix SNP 6.0 Genotyping Data-How Accurate Are Commonly Used Prediction Approaches?

Benchmarking of Approaches for Gene Copy-Number Variation Analysis and Its Utility for Genetic Aberration Detection in High-Grade Serous Ovarian Carcinomas

Amplification of the Ch19p13.2 NACC1 Locus in Ovarian High-Grade Serous Carcinoma

Recurrent chromosome alterations in primary ovarian carcinoma in Chinese women

Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors

Noninvasive early differential diagnosis and progression monitoring of ovarian cancer using the copy number alterations of plasma cell-free DNA

Abstract A027: Genome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma

Functional Genomic Analysis of Chromosomal Aberrations in a Compendium of 8000 Cancer Genomes

Abstract 2418: Copy number variation status of DNA in extracellular vesicles as novel biomarkers of high-grade serous ovarian carcinoma